Conversely, while low plasma LCAT activity has been reported in patients with CAD or acute myocardial infarction [126,127], the relationship between LCAT activity and CVD risk appears to be more complex [128], with weaker evidence to suggest its implementation in clinical practice for CVD screening in the absence of genetic mutations. This evidence concerns the gene LCAT and coronary artery disorder.